S&P 500   3,559.24 (+0.05%)
DOW   29,406.30 (+0.49%)
QQQ   288.68 (-0.59%)
AAPL   114.29 (-2.60%)
MSFT   208.48 (-0.91%)
FB   265.16 (-1.68%)
GOOGL   1,714.00 (-1.29%)
AMZN   3,081.32 (-0.58%)
TSLA   518.70 (+5.94%)
NVDA   523.63 (+0.02%)
BABA   270.51 (-0.08%)
CGC   24.31 (+2.49%)
GE   10.19 (+4.41%)
MU   63.77 (+3.86%)
AMD   86.05 (+1.67%)
T   28.53 (+0.74%)
NIO   52.55 (+6.70%)
F   8.86 (+1.37%)
ACB   7.11 (-0.28%)
GILD   59.54 (-0.95%)
NFLX   483.75 (-0.92%)
BA   207.71 (+4.05%)
DIS   141.78 (+0.50%)
S&P 500   3,559.24 (+0.05%)
DOW   29,406.30 (+0.49%)
QQQ   288.68 (-0.59%)
AAPL   114.29 (-2.60%)
MSFT   208.48 (-0.91%)
FB   265.16 (-1.68%)
GOOGL   1,714.00 (-1.29%)
AMZN   3,081.32 (-0.58%)
TSLA   518.70 (+5.94%)
NVDA   523.63 (+0.02%)
BABA   270.51 (-0.08%)
CGC   24.31 (+2.49%)
GE   10.19 (+4.41%)
MU   63.77 (+3.86%)
AMD   86.05 (+1.67%)
T   28.53 (+0.74%)
NIO   52.55 (+6.70%)
F   8.86 (+1.37%)
ACB   7.11 (-0.28%)
GILD   59.54 (-0.95%)
NFLX   483.75 (-0.92%)
BA   207.71 (+4.05%)
DIS   141.78 (+0.50%)
S&P 500   3,559.24 (+0.05%)
DOW   29,406.30 (+0.49%)
QQQ   288.68 (-0.59%)
AAPL   114.29 (-2.60%)
MSFT   208.48 (-0.91%)
FB   265.16 (-1.68%)
GOOGL   1,714.00 (-1.29%)
AMZN   3,081.32 (-0.58%)
TSLA   518.70 (+5.94%)
NVDA   523.63 (+0.02%)
BABA   270.51 (-0.08%)
CGC   24.31 (+2.49%)
GE   10.19 (+4.41%)
MU   63.77 (+3.86%)
AMD   86.05 (+1.67%)
T   28.53 (+0.74%)
NIO   52.55 (+6.70%)
F   8.86 (+1.37%)
ACB   7.11 (-0.28%)
GILD   59.54 (-0.95%)
NFLX   483.75 (-0.92%)
BA   207.71 (+4.05%)
DIS   141.78 (+0.50%)
S&P 500   3,559.24 (+0.05%)
DOW   29,406.30 (+0.49%)
QQQ   288.68 (-0.59%)
AAPL   114.29 (-2.60%)
MSFT   208.48 (-0.91%)
FB   265.16 (-1.68%)
GOOGL   1,714.00 (-1.29%)
AMZN   3,081.32 (-0.58%)
TSLA   518.70 (+5.94%)
NVDA   523.63 (+0.02%)
BABA   270.51 (-0.08%)
CGC   24.31 (+2.49%)
GE   10.19 (+4.41%)
MU   63.77 (+3.86%)
AMD   86.05 (+1.67%)
T   28.53 (+0.74%)
NIO   52.55 (+6.70%)
F   8.86 (+1.37%)
ACB   7.11 (-0.28%)
GILD   59.54 (-0.95%)
NFLX   483.75 (-0.92%)
BA   207.71 (+4.05%)
DIS   141.78 (+0.50%)
Log in
NASDAQ:MNPR

Monopar Therapeutics Stock Forecast, Price & News

$5.01
-0.09 (-1.76 %)
(As of 11/23/2020 10:43 AM ET)
Add
Compare
Today's Range
$5.01
Now: $5.01▼
$5.01
50-Day Range
$4.36
MA: $4.83▼
$5.25
52-Week Range
$4.28
Now: $5.01▼
$48.00
Volume100 shs
Average Volume59,644 shs
Market Capitalization$57.37 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Monopar Therapeutics Inc., a biopharmaceutical company, engages in developing proprietary therapeutics to enhance clinical outcomes for cancer patients in the United States. It is involved in developing Validive, a clonidine mucobuccal tablet that is in Phase III for the treatment of radiation induced severe oral mucositis in oropharyngeal cancer patients; Camsirubicin, a topoisomerase II-alpha targeted analog of doxorubicin engineered to retain anticancer activity and for minimizing toxic effects on the heart; and MNPR-101, a humanized monoclonal antibody for treating advanced solid cancers. The company has a collaboration Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; and NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19. Monopar Therapeutics Inc. was founded in 2014 and is headquartered in Wilmette, Illinois.
Read More

Beat the Market (BTM) Rank™

Analyst Opinion: 3.5Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

1.49 out of 5 stars


Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MNPR
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.monopartx.com
Phone847-388-0349
Employees6

Debt

Debt-to-Equity Ratio0.01
Current Ratio22.22
Quick Ratio22.22

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book Value$1.19 per share
Price / Book4.21

Profitability

EPS (Most Recent Fiscal Year)($0.45)
Net Income$-4,220,000.00
Net MarginsN/A
Return on Equity-42.87%
Return on Assets-40.63%

Miscellaneous

Outstanding Shares11,452,000
Market Cap$57.37 million
Next Earnings Date3/26/2021 (Estimated)
OptionableNot Optionable
$5.01
-0.09 (-1.76 %)
(As of 11/23/2020 10:43 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive MNPR News and Ratings via Email

Sign-up to receive the latest news and ratings for MNPR and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Monopar Therapeutics (NASDAQ:MNPR) Frequently Asked Questions

How has Monopar Therapeutics' stock price been impacted by Coronavirus?

Monopar Therapeutics' stock was trading at $8.4650 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, MNPR shares have decreased by 40.8% and is now trading at $5.01.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of Monopar Therapeutics?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Monopar Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Monopar Therapeutics.

What stocks does MarketBeat like better than Monopar Therapeutics?

Wall Street analysts have given Monopar Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Monopar Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Monopar Therapeutics' next earnings date?

Monopar Therapeutics is scheduled to release its next quarterly earnings announcement on Friday, March 26th 2021.
View our earnings forecast for Monopar Therapeutics.

How were Monopar Therapeutics' earnings last quarter?

Monopar Therapeutics Inc. (NASDAQ:MNPR) issued its earnings results on Thursday, May, 7th. The company reported ($0.10) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.11) by $0.01.
View Monopar Therapeutics' earnings history.

What price target have analysts set for MNPR?

2 analysts have issued 12 month price objectives for Monopar Therapeutics' shares. Their forecasts range from $11.00 to $42.00. On average, they anticipate Monopar Therapeutics' stock price to reach $26.50 in the next year. This suggests a possible upside of 428.9% from the stock's current price.
View analysts' price targets for Monopar Therapeutics.

Are investors shorting Monopar Therapeutics?

Monopar Therapeutics saw a increase in short interest in the month of October. As of October 30th, there was short interest totaling 42,400 shares, an increase of 19.8% from the October 15th total of 35,400 shares. Based on an average daily trading volume, of 170,600 shares, the short-interest ratio is currently 0.2 days. Approximately 1.6% of the shares of the company are short sold.
View Monopar Therapeutics' Short Interest.

Who are some of Monopar Therapeutics' key competitors?

Some companies that are related to Monopar Therapeutics include CorMedix (CRMD), CorMedix (CRMD), IMV (IMV), Chiasma (CHMA), Aquestive Therapeutics (AQST), Xeris Pharmaceuticals (XERS), Evelo Biosciences (EVLO), OrganiGram (OGI), Neptune Wellness Solutions (NEPT), ESSA Pharma (EPIX), Mustang Bio (MBIO), Veru (VERU), ProQR Therapeutics (PRQR), Chimerix (CMRX) and Otonomy (OTIC).
View all competitors.

What other stocks do shareholders of Monopar Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Monopar Therapeutics investors own include Entasis Therapeutics (ETTX), Fulcrum Therapeutics (FULC), Sorrento Therapeutics (SRNE), Akero Therapeutics (AKRO), Chimerix (CMRX), CorMedix (CRMD), Trevena (TRVN), Aldeyra Therapeutics (ALDX), Advanced Micro Devices (AMD) and Aquestive Therapeutics (AQST).

Who are Monopar Therapeutics' key executives?

Monopar Therapeutics' management team includes the following people:
  • Dr. Chandler D. Robinson M.B.A., M.Sc., MBA, M.D., MSc, Co-Founder, CEO, Pres & Director (Age 36, Pay $541.25k)
  • Ms. Kim R. Tsuchimoto, CFO, Sec. & Treasurer (Age 57, Pay $183.22k)
  • Dr. Andrew P. Mazar, Exec. VP of R&D, Chief Scientific Officer and Director (Age 58, Pay $465.5k)
  • Dr. Patrice P. Rioux, Acting Chief Medical Officer (Age 69)

When did Monopar Therapeutics IPO?

(MNPR) raised $9 million in an IPO on Thursday, December 19th 2019. The company issued 1,100,000 shares at $8.00 per share. JonesTrading served as the underwriter for the IPO and Arcadia Securities was co-manager.

What is Monopar Therapeutics' stock symbol?

Monopar Therapeutics trades on the NASDAQ under the ticker symbol "MNPR."

How do I buy shares of Monopar Therapeutics?

Shares of MNPR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Monopar Therapeutics' stock price today?

One share of MNPR stock can currently be purchased for approximately $5.01.

How big of a company is Monopar Therapeutics?

Monopar Therapeutics has a market capitalization of $57.37 million. The company earns $-4,220,000.00 in net income (profit) each year or ($0.45) on an earnings per share basis. Monopar Therapeutics employs 6 workers across the globe.

What is Monopar Therapeutics' official website?

The official website for Monopar Therapeutics is www.monopartx.com.

How can I contact Monopar Therapeutics?

Monopar Therapeutics' mailing address is 1000 SKOKIE BLVD SUITE 350, WILMETTE IL, 60091. The company can be reached via phone at 847-388-0349 or via email at [email protected]

This page was last updated on 11/23/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.